NGS

Complete Genomics and seqWell Announce Codevelopment Partnership at AGBT

Retrieved on: 
Wednesday, February 7, 2024
Partnership, Genomics, Product management, SAN, Marketing, Complete Genomics, Completeness, Human genetics, DNA, Mass meeting, Society, NGS, Genomic library, Synthetic biology, ASHG

SAN JOSE, Calif. and BEVERLY, Mass., Feb. 7, 2024 /PRNewswire/ -- Complete Genomics, a life sciences company specializing in end-to-end DNA sequencing solutions, and seqWell, a global provider of genomic library preparation workflow solutions, today announced a partnership aimed at expanding the range of library preparation product offerings available to Complete Genomics customers. The companies will work together to ensure seqWell-developed products are compatible with the entire Complete Genomics next-generation sequencing (NGS) and automation portfolios.

Key Points: 
  • The companies will work together to ensure seqWell-developed products are compatible with the entire Complete Genomics next-generation sequencing (NGS) and automation portfolios.
  • "Our partnership with seqWell enables us to offer a broader range of tools to support a broader range of customer needs."
  • Leveraging the power of the Complete Genomics DNBSEQ-G400RS * and seqWell purePlex ™ DNA Library Prep Kit , this partnership will allow customers to the ability to run cost-effective and scalable workflows pairing seqWell library prep kits with Complete Genomics' portfolio of DNBSEQ technologies.
  • The latest outcome of this partnership enables customers to pair seqWell's ExpressPlex ™ library prep kits with Complete Genomics' portfolio of DNBSEQ technologies, including the DNBSEQ-G-99 RS* and DNBSEQ-T7 RS* sequencers.

SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain

Retrieved on: 
Wednesday, February 7, 2024
Sophia Genetics, GENETICS, DNA, Biomarker, Patient, Diagnosis, Laboratory, Corporate Affairs, AstraZeneca, HRR, Ovarian cancer, HRD, Cancer, NGS, Death, Health equity, Hospital, Pharmaceutical industry

BOSTON and ROLLE, Switzerland and MADRID, Feb. 7, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency (HRD) throughout the country. The expansion of the program, supported by AstraZeneca Spain and its network throughout the country, will further SOPHiA GENETICS' commitment to global health equity by making this vital testing available to thousands more patients in the country.

Key Points: 
  • The program from SOPHiA GENETICS and AstraZeneca Spain started in 2022, when AstraZeneca and SOPHiA GENETICS collaborated to deploy HRD testing to five labs throughout the country.
  • With today's announcement, AstraZeneca Spain named SOPHiA GENETICS its preferred partner in deploying HRD testing throughout Spain.
  • Together, SOPHiA GENETICS and AstraZeneca are offering the option for HRD testing to become available to even more laboratories throughout the country to help facilitate in-house HRD detection.
  • Hence our agreement with SOPHiA GENETICS, to offer hospital centers throughout Spain the possibility of making an accurate diagnosis for patients with ovarian cancer."

SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain

Retrieved on: 
Wednesday, February 7, 2024
Sophia Genetics, GENETICS, DNA, Biomarker, Patient, Diagnosis, Laboratory, Corporate Affairs, AstraZeneca, HRR, Ovarian cancer, HRD, Cancer, NGS, Death, Health equity, Hospital, Pharmaceutical industry

BOSTON and ROLLE, Switzerland and MADRID, Feb. 7, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency (HRD) throughout the country. The expansion of the program, supported by AstraZeneca Spain and its network throughout the country, will further SOPHiA GENETICS' commitment to global health equity by making this vital testing available to thousands more patients in the country.

Key Points: 
  • The program from SOPHiA GENETICS and AstraZeneca Spain started in 2022, when AstraZeneca and SOPHiA GENETICS collaborated to deploy HRD testing to five labs throughout the country.
  • With today's announcement, AstraZeneca Spain named SOPHiA GENETICS its preferred partner in deploying HRD testing throughout Spain.
  • Together, SOPHiA GENETICS and AstraZeneca are offering the option for HRD testing to become available to even more laboratories throughout the country to help facilitate in-house HRD detection.
  • Hence our agreement with SOPHiA GENETICS, to offer hospital centers throughout Spain the possibility of making an accurate diagnosis for patients with ovarian cancer."

Volta Labs and Integrated DNA Technologies Partner to Advance Target Enrichment Workflows

Retrieved on: 
Tuesday, February 6, 2024
Partnership, Agitation, Workflow, IDT, Integrated DNA Technologies, Genomics, Learning, NGS, Library, Callisto, Integration, Fine chemical

Volta Labs and IDT are working to create platform-agnostic solutions, with the goal of walk-away sample prep, starting with target enrichment workflows.

Key Points: 
  • Volta Labs and IDT are working to create platform-agnostic solutions, with the goal of walk-away sample prep, starting with target enrichment workflows.
  • Initial study shows capture metrics and variant calling results were comparable or better for libraries processed using the Volta Labs benchtop instrument.
  • "We look forward to working closely with Volta to advance sample prep approaches and enable higher quality sequencing metrics which are especially important in target enrichment workflows like oncology applications."
  • "IDT is focused on optimizing tools and solutions that enable a higher degree of NGS performance," said Udayan Umapathi, CEO at Volta Labs.

Twist Bioscience Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications

Retrieved on: 
Tuesday, February 6, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Whole genome sequencing, Liquid biopsy, Twist Bioscience, Workflow, DNA, Circulating tumor DNA, Patient, Doctor of Philosophy, Disease, Silicon, Neoplasm, NGS, Twist, WGS, Cancer, MRD, Nucleic acid thermodynamics

The Twist cfDNA Library Preparation Kit was purpose-built to maximize the number of unique cfDNA molecules that are captured in library preparation, for higher confidence in the accuracy and sensitivity of liquid biopsy tests.

Key Points: 
  • The Twist cfDNA Library Preparation Kit was purpose-built to maximize the number of unique cfDNA molecules that are captured in library preparation, for higher confidence in the accuracy and sensitivity of liquid biopsy tests.
  • With exceptional accuracy and sensitivity enabled by high conversion rates, the Twist cfDNA Library Preparation Kit can help push the limit of detection and detect lower frequency variants that can be missed by other on market library preparation solutions.”
    The Twist cfDNA Library Preparation Kit adds to Twist’s growing portfolio of tools to support the research and development of liquid biopsy assays, which also includes the recently launched Twist cfDNA Pan-Cancer Reference Standard v2 .
  • The Twist cfDNA Library Preparation Kit can address challenges associated with library preparation from circulating cfDNA with reliable and robust performance from as little as 1ng sample input.
  • The Twist cfDNA Library Preparation Kits are available in two configurations: the cfDNA Library Preparation Kit for whole genome sequencing (WGS) workflows and the Twist Library Preparation and Hyb Mix Kit for target enrichment.

Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System

Retrieved on: 
Tuesday, February 6, 2024
Research, General Health, Biometrics, Technology, Genetics, Health Technology, Public Relations, Investor Relations, Science, Nanotechnology, Biotechnology, Communications, Health, Other Science, Multimedia, Twist Bioscience, Workflow, Doctor of Philosophy, Exome, Learning, Silicon, NGS, Element, Fine chemical

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc. , developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc. , developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.
  • View the full release here: https://www.businesswire.com/news/home/20240206284355/en/
    “Element continues to expand its customer base, bringing high quality and cost-effective sequencing to researchers globally.
  • Pairing Twist’s robust NGS workflows with Element’s AVITI technology will offer customers an economical and streamlined approach to next generation sequencing,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • If interested in learning more about the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow, please reach out here .

Singular Genomics Showcases New G4X™ Spatial Sequencer at AGBT and Announces Significant Advances in Throughput, Quality, and Usability for G4® Sequencing Platform

Retrieved on: 
Monday, February 5, 2024
SAN, G4S, RNA, Genome Biology, OMIC, Proteomics, Tissue, NGS, F4, Medical imaging

Singular unveiled the G4X™ Spatial Sequencer as a high-throughput in situ spatial sequencing platform capable of simultaneous direct RNA sequencing, targeted transcriptomics, proteomics and fluorescent H&E from formalin-fixed, paraffin-embedded (FFPE) tissues.

Key Points: 
  • Singular unveiled the G4X™ Spatial Sequencer as a high-throughput in situ spatial sequencing platform capable of simultaneous direct RNA sequencing, targeted transcriptomics, proteomics and fluorescent H&E from formalin-fixed, paraffin-embedded (FFPE) tissues.
  • As an upgrade to the G4® Sequencing Platform, the G4X is expected to position Singular to be the only company worldwide to offer capabilities for tissue-based in situ spatial multiomics and NGS on the same instrument.
  • The G4X Spatial Sequencer is on display at the conference, alongside performance data from technology access collaborations with top academic centers.
  • Singular also announced updates to the G4, the industry-leading benchtop sequencing system for speed, flexibility, and power.

Singular Genomics Unveils G4X™ Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis

Retrieved on: 
Monday, February 5, 2024
Genomics, Tumor microenvironment, SAN, Protein, Workflow, Cell, RNA, Gene editing, Research, PX, Bone marrow, Haematopoietic system, OMIC, AML, Harvard Medical School, Proteomics, Associate professor, NGS, Tissue, Acute leukemia, Network throughput, Medical imaging

The G4X is designed to offer high-throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues.

Key Points: 
  • The G4X is designed to offer high-throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues.
  • The G4X Spatial Sequencer is designed to offer novel capabilities, stackable data streams, and unprecedented throughput for spatial profiling of tissue.
  • Its novel capabilities will include Direct-Seq, which is the sequencing of RNA molecules in situ and has the potential to open new areas of scientific discovery.
  • Singular also plans to provide G4X Spatial Sequencing Technology Access Services starting in the second quarter of 2024.

Global Sequencing Kits Market Analysis Report 2023-2030: Market Driven by Rising Prevalence of Genetic Disorders, Genome Mapping Programs and Decreasing Sequencing Costs Propel Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, February 5, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Developed country, Growth, DSM-IV codes, Research, SMRT, DNA, Government, Biomarker, Prevalence, Incidence, Genetic testing, Drug discovery, Medicine, Genomics, Proteomics, NGS, Cancer, Fine chemical

The "Sequencing Kits Market by Type Technology Application End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sequencing Kits Market by Type Technology Application End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global sequencing kits market is projected to reach $21.9 billion by 2030, at a CAGR of 15.3% from 2023 to 2030.
  • However, the high costs of sequencing kits & reagents and the ethical & legal issues related to DNA sequencing-based diagnosis are factors restraining the growth of this market.
  • Additionally, developing portable sequencing technologies and increasing partnerships & collaborations among NGS product manufacturers to expand and improve product offerings are prominent trends in the sequencing kits & reagents market.

Takara Bio’s First-to-Market Large-Scale Single-Cell NGS Profiling Technologies Poised to Revolutionize Biomarker Discovery

Retrieved on: 
Monday, February 5, 2024
Oncology, Medical Supplies, Health, Genetics, Research, Science, Biotechnology, Neoplasm, Cell, B cell, Biomarker, CNV, RNA-Seq, NGS, RNA, SNV, Antibiotics

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced plans to launch two critical solutions for oncology research.

Key Points: 
  • Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced plans to launch two critical solutions for oncology research.
  • The Shasta™ Total RNA-Seq Kit will detect splicing isoforms, gene fusions, and non-polyadenylated RNAs through full-length transcriptome profiling of up to 100,000 single cells per run.
  • “Our new kits will break the limits of current methods to enable true biological discovery,” said Carol Lou, President & CEO of Takara Bio USA.
  • With the new Shasta™ technologies, Takara Bio will introduce first-to-market high-scale solutions that can pick up important genetic events other technologies miss.